Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study [Breast Cancer]

Conclusion This phase Ib study describes preliminary evidence of clinical activity and a potentially acceptable safety profile of pembrolizumab given every 2 weeks to patients with heavily pretreated, advanced TNBC. A single-agent phase II study examining a 200-mg dose given once every 3 weeks (ClinicalTrials.gov identifier: NCT02447003) is ongoing.

http://jco.ascopubs.org/cgi/content/short/34/21/2460?rss=1

Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Nanda, Chow, Dees, Berger, Gupta, Geva, Pusztai, Pathiraja, Aktan, Cheng, Karantza, Buisseret Tags: Chemotherapy, Phase I and Clinical Pharmacology, Breast Imaging Breast Cancer Source Type: research